Cambridge Investment Research Advisors
VRCA icon

Cambridge Investment Research Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,150
Closed -$6K – 3873
2025
Q2 		$6K Hold
1,150
– – ﹤0.01% 3602
2025
Q1 		$5K Hold
1,150
– – ﹤0.01% 3491
2024
Q4 		$8K Hold
1,150
– – ﹤0.01% 3449
2024
Q3 		$17K Hold
1,150
– – ﹤0.01% 3374
2024
Q2 		$84K Hold
1,150
– – ﹤0.01% 3178
2024
Q1 		$68K Buy
+1,150
New +$63.5K ﹤0.01% 3187

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Cambridge Investment Research Advisors's VRCA Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 1,150 shares — an estimated $6K sold.

Cambridge Investment Research Advisors first reported a position in VRCA in Q1 2024 and held it in 6 quarters. The position peaked at $84K in Q2 2024. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,150 Verrica Pharmaceuticals shares in Q3 2025, an estimated $6K.
  • Cambridge Investment Research Advisors first reported a position in Verrica Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's Verrica Pharmaceuticals position peaked at $84K in Q2 2024.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.